(Q50576324)

15 March 2018

title

Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-beta1, and metalloproteinase activity in chronic hepatitis C. (English)

1 reference

15 March 2018

1 reference

1 reference

4

1 reference

15 March 2018

author name string

Maria Guido

1

1 reference

15 March 2018

Lucia De Franceschi

2

1 reference

15 March 2018

Nicola Olivari

3

1 reference

15 March 2018

Martina Felder

5

1 reference

15 March 2018

Roberto Corrocher

6

1 reference

15 March 2018

Massimo Rugge

7

1 reference

15 March 2018

Michela Pasino

8

1 reference

15 March 2018

Cristiano Lanza

9

1 reference

15 March 2018

Paola Capelli

10

1 reference

15 March 2018

Giovanna Fattovich

11

1 reference

15 March 2018

publication date

12 May 2006

1 reference

15 March 2018

published in

Modern Pathology

1 reference

15 March 2018

volume

19

1 reference

15 March 2018

issue

8

1 reference

15 March 2018

page(s)

1047-1054

1 reference

15 March 2018

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Hepatitis C and liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Cytokine receptors and signaling in hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Series introduction: the transcription factor NF-kappaB and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

NF-kappaB/rel/IkappaB: implications in gastrointestinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: decreased RelA expression is associated with enhanced fibrosis progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Intragraft localization of activated nuclear factor kappaB in recurrent hepatitis C virus disease following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Role of transforming growth factor beta in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Roles of TGF-beta in hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Transforming growth factor-beta 1 in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Extracellular matrix remodelling: the role of matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Role of metalloproteinases in liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Liver fibrosis: from the bench to clinical targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

In situ expression of transforming growth factor-beta1-3, latent transforming growth factor-beta binding protein and tumor necrosis factor-alpha in liver tissue from patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Possible new role for NF-kappaB in the resolution of inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Matrix metalloproteinases and their inhibitors in acute viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

7 January 2021

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

7 January 2021

Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

7 January 2021

Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

7 January 2021

Activation of nuclear factor-kappaB and its proinflammatory mediator cascade in the infarcted rat heart

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

7 January 2021

Nuclear factor kappaB and hepatitis C--Is there a connection?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

7 January 2021

Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800592

7 January 2021

10.1038/MODPATHOL.3800592

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018